When Pete Mariani joined Axogen in early 2016 as its CFO, the company’s products were making a difference in the lives of people with nerve damage, but it was under-capitalized and lacked a sizable investor base. The reason was bad timing. Back in 2007, just as it was considering going public to capitalize on the release […]

When it comes to cell therapies, most companies choose to focus on DNA rather than RNA. Cartesian Therapeutics is a Gaithersburg, Maryland based biopharma firm focused on pioneering mRNA-engineered cell therapies for oncology, respiratory and autoimmune diseases. Made up of an integrated team of scientists, Cartesian’s vision is to cure disease using mRNA, aiming to […]

On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer’s treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the build up of a protein known as beta amyloid that some think might be one of the possible causes of Alzheimer’s disease. While the approval […]